What is Island Pharmaceuticals Limited's (ILA.AX) StockRank?

MoatMap's StockRank for Island Pharmaceuticals Limited (ILA.AX) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (19), Value (20), and Momentum (32) factor ranks across MoatMap's 20,000+ stock universe.

Does Island Pharmaceuticals Limited have an economic moat?

Island Pharmaceuticals Limited (ILA.AX) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Island Pharmaceuticals Limited a buy, hold, or sell?

MoatMap's current signal for Island Pharmaceuticals Limited (ILA.AX) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Island Pharmaceuticals Limited in?

Island Pharmaceuticals Limited (ILA.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ILA.AX

STRONG SELLREMOVE

Island Pharmaceuticals Limited · Healthcare · Australia · $76M · Avg Vol: $93K/d

StockRank

P/E (TTM)

—

ROE

-130.3%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Early-stage drug development company with highly speculative pipeline and no established commercial moat or pricing power.

COMPANY DESCRIPTION

Island Pharmaceuticals Limited is a clinical-stage biotechnology company focused on developing preventative and therapeutic antiviral drugs for infectious diseases, with a primary focus on dengue fever. The company's lead drug candidate, ISLA-101, is a repurposed compound, which significantly reduces development costs, timelines, and regulatory risks. Island's competitive advantage lies in its rapid-to-clinic development strategy and its focus on high-growth, underserved tropical disease markets.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	—	7,748	0.9M	—	11211.1%
EPS	—	-0.01	-0.01	-0.01	-0.01	—
Shares	—	295.9M	295.9M	295.9M	295.9M	0.0%
Debt	—	0.2M	0.4M	0.2M	0.3M	21.2%
Equity	—	4.5M	3.0M	1.3M	1.1M	-38.1%
Op CF	—	—	—	—	—	—
Inv CF	—	54,178	—	—	—	—
Fin CF	—	5.1M	—	-0.1M	2.0M	—

PRICE (1Y)+10.4%

SMA 50SMA 200

$0.26

RSI (14)

51.5

52W High

$0.44

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC (ROA)

-74.7%*7.9

ROE

-130.3%6.0

GP/Assets

-84.3%0.4

Op. Margin

-12053.0%1.8

FCF/Assets

-99.6%1.2

Piotroski

238.9

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

8.40x83.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

13.5x8.2

P/S

1718.5x2.4

Div Yield

—N/A

Momentum

52W High %

59%33.9

RS 6M

-24%47.9

SMA 50/200

0.91x38.1

EPS Rev 4W

-8.8%6.4

EPS Rev 12W

—N/A

EPS Improve

-57%8.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$76M

P/E (Forward)

-7.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ILA.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ILA.AX	Island Pharmaceuticals Limited(you)	$76M	3	STRONG SELL
NYR.AX	Nyrada Inc.	$79M	1	STRONG SELL
LTP.AX	LTR PHARMA FPO [LTP]	$71M	6	STRONG SELL
PAR.AX	Paradigm Biopharmaceuticals Limited	$70M	0	STRONG SELL
DXB.AX	Dimerix Limited	$92M	1	STRONG SELL
ACW.AX	Actinogen Medical Limited	$87M	9	STRONG SELL
IMM.AX	Immutep Limited	$54M	5	STRONG SELL
ATH.AX	Alterity Therapeutics Limited	$90M	15	STRONG SELL
OCC.AX	Orthocell Limited	$146M	14	STRONG SELL
RAC.AX	Racura Oncology Ltd	$330M	10	STRONG SELL

Peer medians: ROE -18.2% · P/E 21.1x · Gross margin 49.7%

Island Pharmaceuticals Limited (ILA.AX) — Stock Score Summary

Island Pharmaceuticals Limited (ILA.AX) has a MoatMap StockRank of 3/100 based on Quality (19/100), Value (20/100), and Momentum (32/100) factor scores. The current signal is STRONG SELL. Early-stage drug development company with highly speculative pipeline and no established commercial moat or pricing power.

Key Financial Metrics

Price	$0.26
Market Cap	$76M
P/E (Forward)	-7.77
Price/Book	13.52
Return on Equity	-130.3%
Gross Margin	0.0%
Operating Margin	-12053.0%
Revenue Growth	-57.9%
Free Cash Flow	$-1M

Island Pharmaceuticals Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Island Pharmaceuticals Limited’s (ILA.AX) StockRank?: MoatMap’s StockRank for Island Pharmaceuticals Limited (ILA.AX) is 3/100, with a Strong Sell signal. It is a composite of Quality (19), Value (20), and Momentum (32) factor ranks across MoatMap’s 20,000+ stock universe.
Does Island Pharmaceuticals Limited have an economic moat?: Island Pharmaceuticals Limited (ILA.AX) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Island Pharmaceuticals Limited a buy, hold, or sell?: MoatMap’s current signal for Island Pharmaceuticals Limited (ILA.AX) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Island Pharmaceuticals Limited in?: Island Pharmaceuticals Limited (ILA.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).